12. The antisense oligonucleotide according to any one of claims **1-11**, wherein the oligonucleotide comprises or consists of a contiguous nucleotide sequence, selected from the group consisting of: CCttctcatataaaaCACA (SEQ ID NO 54);

CTTtactacactccCT (SEQ ID NO 55); CCACtaattcttaaaattC (SEQ ID NO 56);

CCaacaattacttcTCAA (SEQ ID NO 57); CTGatttacaacctcATC (SEQ ID NO 58);

TATttttctccaaaattCC (SEQ ID NO 59); CTCAttcatccaacaaatAA (SEQ ID NO 60);

CACtaaaacatcctaaaaCC (SEQ ID NO 61); TTCCattcttactctttAA (SEQ ID NO 62);

ACActatattctacctaATC (SEQ ID NO 63); CCtttcccattaaaaaATTT (SEQ ID NO 64);

ACCTtccatttaacattAC (SEQ ID NO 65); ATCtaccattcaacaaaCAC (SEQ ID NO 66);

TGTaacttaatcttCCT (SEQ ID NO 67); CAtcctaaccttattatTAT (SEQ ID NO 68);

CCctaacattcctatTTA (SEQ ID NO 69); CCttcaatctaatcTTTA (SEQ ID NO 70);

ACcttgaatactccTCA (SEQ ID NO 71); TTCActacctcccaaAT (SEQ ID NO 72);

ATCtcacacacaataatCAC (SEQ ID NO 73); CTCAcacacaataatcaCT (SEQ ID NO 74);

ATAtattcctttacataCAA (SEQ ID NO 75); TATAttcctttacatacaAC (SEQ ID NO 76);

ATattcctttacatacaACT (SEQ ID NO 77); TATTcctttacatacaacTT (SEQ ID NO 78);

ATtcctttacatacaaCTTT (SEQ ID NO 79); GCCaacatttatccAC (SEQ ID NO 80);

CCAacatttatccACT (SEQ ID NO 81); CTaaaactccataccTCA (SEQ ID NO 82);

CCcagacattacacCA (SEQ ID NO 83); CCagacattacaccaTTC (SEQ ID NO 84);

AGAcattacaccatTCA (SEQ ID NO 85); AAacagtaatcccTTCA (SEQ ID NO 86);

ACAgtaatcccttcaCT (SEQ ID NO 87); CAGtaatcccttcacTT (SEQ ID NO 88);

AGtaatcccttcacttTA (SEQ ID NO 89); TAatcccttcacttataTAT (SEQ ID NO 90);

TATTaacacaaacacattCA (SEQ ID NO 91); ACAcaaacacattcaatCAT (SEQ ID NO 92);

CACAaacacattcaatcaTA (SEQ ID NO 93); ACAaacacattcaatcaTAT (SEQ ID NO 94);

CAaacacattcaatcaTATC (SEQ ID NO 95); TGAcaaatcctaaTCT (SEQ ID NO 96);

TTAccttacccattaTC (SEQ ID NO 97); TAccttacccattatcTT (SEQ ID NO 98);

TACccttacatccATA (SEQ ID NO 99); AAAtacccttacatccaTAA (SEQ ID NO 100);

ACccttacatccaTAAT (SEQ ID NO 101); CCTtacatccataatcAT (SEQ ID NO 102); and

CTTAcatccataatcatTT (SEQ ID NO 103), wherein a capital letter represents a LNA nucleoside, a lower case letter represents a DNA nucleoside.

13. The antisense oligonucleotide according to any one of claims **1-12**, wherein the oligonucleotide comprises or consists of a contiguous nucleotide sequence, selected from the group consisting of: CCttctcatataaaaCACA (SEQ ID NO 54);

CTTtactacactccCT (SEQ ID NO 55); CCACtaattcttaaaattC (SEQ ID NO 56);

CCaacaattacttcTCAA (SEQ ID NO 57); CTGatttacaacctcATC (SEQ ID NO 58);

TATttttctccaaaattCC (SEQ ID NO 59); CTCAttcatccaacaaatAA (SEQ ID NO 60);

CACtaaaacatcctaaaaCC (SEQ ID NO 61); TTCCattcttactctttAA (SEQ ID NO 62);

ACActatattctacctaATC (SEQ ID NO 63); CCtttcccattaaaaaATTT (SEQ ID NO 64);

ACCTtccatttaacattAC (SEQ ID NO 65); ATCtaccattcaacaaaCAC (SEQ ID NO 66);

TGTaacttaatcttCCT (SEQ ID NO 67); CAtcctaaccttattatTAT (SEQ ID NO 68);

CCctaacattcctatTTA (SEQ ID NO 69); CCttcaatctaatcTTTA (SEQ ID NO 70);

ACcttgaatactccTCA (SEQ ID NO 71); TTCActacctcccaaAT (SEQ ID NO 72);

ATCtcacacacaataatCAC (SEQ ID NO 73); CTCAcacacaataatcaCT (SEQ ID NO 74);

ATAtattcctttacataCAA (SEQ ID NO 75); TATAttcctttacatacaAC (SEQ ID NO 76);

ATattcctttacatacaACT (SEQ ID NO 77); TATTcctttacatacaacTT (SEQ ID NO 78);

ATtcctttacatacaaCTTT (SEQ ID NO 79); GCCaacatttatccAC (SEQ ID NO 80);

CCAacatttatccACT (SEQ ID NO 81); CTaaaactccataccTCA (SEQ ID NO 82);

CCcagacattacacCA (SEQ ID NO 83); CCagacattacaccaTTC (SEQ ID NO 84);

AGAcattacaccatTCA (SEQ ID NO 85); AAacagtaatcccTTCA (SEQ ID NO 86);

ACAgtaatcccttcaCT (SEQ ID NO 87); CAGtaatcccttcacTT (SEQ ID NO 88);

AGtaatcccttcacttTA (SEQ ID NO 89); TAatcccttcacttataTAT (SEQ ID NO 90);

TATTaacacaaacacattCA (SEQ ID NO 91); ACAcaaacacattcaatCAT (SEQ ID NO 92);

CACAaacacattcaatcaTA (SEQ ID NO 93); ACAaacacattcaatcaTAT (SEQ ID NO 94);

CAaacacattcaatcaTATC (SEQ ID NO 95); TGAcaaatcctaaTCT (SEQ ID NO 96);

TTAccttacccattaTC (SEQ ID NO 97); TAccttacccattatcTT (SEQ ID NO 98);

TACccttacatccATA (SEQ ID NO 99); AAAtacccttacatccaTAA (SEQ ID NO 100);

ACccttacatccaTAAT (SEQ ID NO 101); CCTtacatccataatcAT (SEQ ID NO 102); and

CTTAcatccataatcatTT (SEQ ID NO 103), wherein a capital letter represents a beta-D-oxy LNA nucleoside, a lower case letter represents a DNA nucleoside, wherein each LNA cytosine is 5-methyl cytosine, and wherein the internucleoside linkages between the nucleosides are phosphorothioate internucleoside linkages.

14. A conjugate comprising the oligonucleotide according to any one of claims **1-13**, and at least one conjugate moiety covalently attached to said oligonucleotide.

15. A pharmaceutical composition comprising the oligonucleotide of claim **1-13** or the conjugate of claim **14** and a pharmaceutically acceptable diluent, solvent, carrier, salt and/or adjuvant.

16. An in vivo or in vitro method for modulating TIA1 expression in a target cell which is expressing TIA1, said method comprising administering an oligonucleotide of any